Abstract Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by pancytopenia and multiple organ infiltrations of lymphocytes and histiocytes with proliferation and hemohpagocytic activity. HLH is classified as primary (or familial) and secondary. Familial HLH is common in infants and young children, and is related to genetic defects. This article aims to review research advances on PRF1, UNC13D, STX11 and STXBP2, as well as the other 5 genes associated with familial HLH based on molecular genetics, and to summarize diagnosis and treatment methods for this disease.
LV Xi-Qian,HU Jian. Research advances in molecular genetics and treatment of familial hemophagocytic lymphohistiocytosis[J]. CJCP, 2013, 15(11): 965-969.
LV Xi-Qian,HU Jian. Research advances in molecular genetics and treatment of familial hemophagocytic lymphohistiocytosis[J]. CJCP, 2013, 15(11): 965-969.
Behrens EM. Macrophage activation syndrome in rheumatic disease: What is the role of the antigen presenting cell?[J]. Autoimmun Rev, 2008, 7(4): 305-308.
[2]
Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation[J]. Blood, 2002, 100(23): 67-73.
[3]
Sieni E, Cetica V, Piccin A, Gherlinzoni F, Sasso FC, Rabusin M, et al. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series[J]. PLoS ONE, 2012, 7(9): e44649.
[4]
Henter JI．Biology and treatment of familial hemophagocytie lymphohistiocytosis: importantce of perforinin lymphocyte mediated cytotoxicity and triggering of apoptosis[J]. Med Pediatr Oncol, 2002, 38(5): 305-309．
[5]
Pachlopnik Schmid J, Cote M, Menager MM, Burgess A, Nehme N, Menasche G, et al. Inherited defects in lymphocyte cytotoxic activity[J]. Immunol Rev, 2010, 235(1): 10-23.
[6]
Cetica V, Pende D, Griffiths GM, Arico M. Molecular basis of familial hemophagocytic lymphohistiocytosis[J]. Haematologica, 2010, 95(4): 538-541.
[7]
Ohadi M, Lalloz MR, Sham P, Zhao J, Dearlove AM, Shiach C, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping[J]. Am J Hum Genet, 1999, 64(1): 165-171.
[8]
Dufourcq-Lagelouse R, Jabado N, Le Deist F, Stephan JL, Souillet G, Bruin M, et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q2l-22 and evidence for heterogeneity[J]. Am J Hum Genet, 1999, 64(1): 172-179．
[9]
zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A[J]. Hum Mutat, 2006, 27(1): 62-68.
[10]
Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA. Perforin: structure, function, and role in human immunopathology[J]. Immunol Rev, 2010, 235(1): 35-54.
[11]
Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer[J]. Proc Natl Acad Sci USA, 2009, 106(24): 9809-9814.
[12]
Ueda I, Morimoto A, Inaba T, Yagi T, Hibi S, Sugimoto T, et al. Characterisation perforin gone mutations of haemophagocytic lymphohistiocytosis patients in Japan[J]. Br J Haematol, 2003, 121(3): 503-510．
[13]
Trizzino A, zur Stadt U, Ueda I, Risma K, Janka G, Ishii E, et al. Genotype-phenotype study of study familial haemophagocytic lymphohistiocytosis due to perforin mutations[J]. J Med Genet, 2008, 45(1): 15-21.
Martinez-Pomar N, Lanio N, Romo N, Lopez-Botet M, Matamoros N. Functional impact of A91V mutation of the PRF1 perforin gene[J]. Human Immunol, 2013, 74(1): 14-17.
[16]
Sieni E, Cetica V, Santoro A, Beutel K, Mastrodicasa E, Meeths M, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3[J]. J Med Genet, 2011, 48(5): 343-352.
[17]
Yoon HS, Kim HJ, Yoo KH, Sung KW, Koo HH, Kang HJ, et al. UNCl3D is the predominant causative gene with recurrent Splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis[J]. Haematologica, 2010, 95(4): 622-626.
[18]
Seo JY, Song JS, Lee KO, Won HH, Kim JW, Kim SH, et al. Founder effects in two predominant intronic mutations of UNC13D c.118-308C>T and c.754-1G>C underlie the unusual predominance of type 3 familial hemophagocytic lymphohistiocytosis (FHL3) in Korea[J]. Ann Hematol, 2013, 92(3): 357-364.
[19]
Garrett JP, Fung I, Rupon J, Knight A, Mizesko M, Paessler M, et al. Presentation of hemophagocytic lymphohistiocytosis due to a novel MUNC 13-4 mutation masked by partial therapeutic immunosuppression[J]. Pediatr Rheumatol, 2012, 10(13): 1-8.
de Saint Basile G, Menasche G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules[J]. Nat Rev Immunol, 2010, 10(8): 568-579.
[22]
Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis4(FHL4)patients[J]. Blood, 2007, 110(6): 1906-1915.
[23]
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, et al. STXll mutations and clinical phenotypes of familial hemophagoeytic lymphohistiocytosis in North America[J]．Pediatr Blood Cancer, 2010, 55(1): 134-140．
[24]
Jain R, Puliyel M, Moses PD, Sieni E. Novel STXBP2 mutation causing familial hemophagocytic lymphohistiocytosis[J]. Indian Pediatr, 2012, 49(6): 488-490.
[25]
zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, et a1. Familial hemophagocytic lymphohistiocytosis type 5(FHL-5)is caused by mutations in Muncl8-2 and impaired binding to syntaxin 11[J]. Am J Hum Genet, 2009, 85(4): 482-492．
[26]
Cetica V, Santoro A, Gilmour KC, Sieni E, Beutel K, Pende D, et al. STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type5[J]. J Med Genet, 2010, 47: 595-600.
[27]
Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome[J]. Nat Genet, 2000, 25(2): 173-176.
[28]
Rihani R, Barbar M, Faqih N, Halalsheh H, Hussein AA, Al-Zaben AH, et al. Unrelated cord blood transplantation can restore hematologic and immunologic functions in patients with Chediak-Higashi Syndrome[J]. Pediatr Transplant, 2012, 16(4): E99-E105.
[29]
Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II[J]. Blood , 2006, 108(1): 81-87.
[30]
Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease[J]. Nat Rev Immunol, 2003, 3(10): 813-821.
[31]
Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome[J]. Nature, 2006, 444(7115): 110-114.
[32]
Sepulveda FE, Debeurme F, Menasche G, Kurowska M, Cote M, Pachlopnik Schmid J, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11[J]. Blood, 2013, 121(4): 595-603.
[33]
Latour S. Natural killer T cells and X-linked lymphoproliferative syndrome[J]. Curr Opin Allergy Clin Immunol, 2007, 7(6): 5l0-514.
[34]
Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnosis and therapeutic guideline for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131.
[35]
Imoshuku S. Clinical features and treatment strategies of Epstein-Burr virus-associated hemophagocytic lymphohistiocytosis[J]. Crit Rev Oncol Hematol, 2002, 44(3): 259-272．
Lackner H, Urban C, Sovinz P, Benesch M, Moser A, Schwinger W. Hemophagoeytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children[J]. Haematologica, 2008, 93(2): 291-294．
[38]
Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2[J]. Blood, 2010, 116(26): 35-43.
Kessler EA, Vora SS, Verbsky JW. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome[J].Pediatr Rheumatol Online J, 2012, 10(1): 30.
[43]
Chung TW. CNS involvement in hemophagocytic lymphohistiocytosis: CT and MR findings[J]. Korean J Radiol, 2007, 8(1): 78-81.
[44]
Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis(EBV-HLH)[J]. J Pediatr Hematol Oncol, 2011, 33(1): 35-39.
